Physician

Laura Nicole Howe, M.D.

According to 2025 Medicare claims, Laura Howe, M.D. (NPI: 1245678648) practices rheumatology in the Greeley, CO market, with the plurality of this provider's patient population coming from Weld, CO. This provider's primary affiliated billing organization is POUDRE VALLEY MEDICAL GROUP, LLC (NPI: 1366763260; TIN: 800348943) and primary practice location at 80538-9004. Howe is affiliated with the Caravan Collaborative Pathways (ACO ID: A4604), Banner Network Colorado, LLC (ACO ID: A4768), Caravan Health ACO 50 LLC (ACO ID: A5160), and CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Howe's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 427 traditional Medicare patients, billed 72,664 HCPCS/CPT codes, and received $1,143,372 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 5,483 prescription claims across 666 beneficiaries totaling $12,642,302 in drug costs, led by Humira(Cf) Pen (Adalimumab). Open Payments data shows 41 records totaling $643. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $3,189 to $12,642,302. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	277	13,372	$277,771
2019	472	50,784	$1,139,842
2020	420	66,159	$1,295,265
2021	441	93,311	$1,396,184
2022	471	107,923	$1,630,073
2023	463	81,613	$1,371,219
2024	427	72,664	$1,143,372

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	15	68	$3,189
2016	36	107	$13,000
2017	56	285	$133,428
2018	279	879	$474,279
2019	467	2,828	$1,609,997
2020	519	3,760	$3,042,193
2021	560	4,242	$5,455,068
2022	624	4,917	$8,642,604
2023	642	5,128	$10,889,754
2024	666	5,483	$12,642,302

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	65	106	$91
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	205	336	$90
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	250	350	$62
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	329	574	$12
96372	Injection of drug or substance under skin or into muscle	54	115	$11

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Humira(Cf) Pen	Adalimumab	256	7,174	$2,375,164
Skyrizi Pen	Risankizumab-Rzaa	83	5,694	$1,769,085
Cosentyx Sensoready (2 Pens)	Secukinumab	195	5,484	$1,502,184
Otezla	Apremilast	251	7,494	$1,232,615
Rinvoq	Upadacitinib	115	3,750	$814,619

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	41	$643	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Laura Nicole Howe, M.D.?

Tedicare shows public-source Medicare data for Laura Nicole Howe, M.D. (NPI 1245678648), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Laura Nicole Howe, M.D. have ACO affiliation data?

Laura Nicole Howe, M.D. is shown with ACO affiliation data for Caravan Collaborative Pathways (MSSP, ACO ID A4604), Banner Network Colorado, LLC (MSSP, ACO ID A4768), Caravan Health ACO 50 LLC (MSSP, ACO ID A5160), and CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Laura Nicole Howe, M.D.?

Laura Nicole Howe, M.D. is linked to POUDRE VALLEY MEDICAL GROUP, LLC (billing NPI 1366763260) in the available physician profile data.

Does Laura Nicole Howe, M.D. have Open Payments data?

Laura Nicole Howe, M.D. has 41 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.